1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 | Furthermore, based on resident 1 (R1) Quick MAR records for the month of March 2023, it was learned that 12 out of 14 medications were not marked as being administered to (R1). For the month of September 2023, it was learned that 12 out of 16 medications were not marked as being administered to (R1). For the month of October 2023, it was learned that 14 out of 14 medications were not marked as being administered to (R1). For the month of November 2023, it was learned that 15 out of 15 medications were not marked as being administered to (R1). (R1) medications for Brimonidine Tartrate 0.2% Solution and Dorzolamide HCL-Timolol MAL 22.3-6.8 solution were not marked as being administered to (R1) for the month of March, September, October, and November.
Based on records review, and interviews, the preponderance of evidence standard has been met, therefore the above allegations are found to be SUBSTANTIATED. Per California Code of Regulations, Title 22, citations for deficiencies can be found on the LIC 9099 -D. Failure to correct deficiencies may result in additional civil penalties. Appeal Rights provided. An exit interview was held, and a copy of the report was provided.
|